<DOC>
	<DOCNO>NCT01723475</DOCNO>
	<brief_summary>This first study BAY2010112 give human . Patients castration resistant prostate cancer treat . Every patient receive drug treatment , placebo group . Patients receive different dosage BAY2010112 determine safety , tolerability maximum tolerate dose ( MTD ) BAY2010112 . The study also assess pharmacokinetics clinical efficacy BAY2010112 . BAY2010112 give daily subcutaneous injection continuous intravenous infusion . Treatment stop tumor continue grow , side effect , patient tolerate , occur patient decides exit treatment .</brief_summary>
	<brief_title>First-in-man Dose Escalation Study BAY2010112 Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male subject , age &gt; /= 18 year Subjects histologically cytologically proven advanced castrationresistant prostate cancer ( CRPC ) fail least 1 taxane regimen refractory abiraterone and/or enzalutamide therapy OR actively refuse treatment would regard standard . Subjects undergone bilateral orchiectomy continuous androgen deprivation therapy gonadotropin release hormone agonist antagonist . Subjects must show progressive disease discontinuation antiandrogen therapy ( i.e . flutamide , bicalutamide nilutamide ) study drug treatment . Total serum testosterone le 50 ng/ml 1.7 nmol/L Evidence progressive disease , define one ( Prostate Cancer Working Group 2 ( PCWG2 ) criterion ) : PSA level least 2 ng/ml rise least 2 successive occasion least 1 week apart Nodal ( lymph node &gt; /= 2cm ) visceral progression define Response Evaluation Criteria Solid Tumors ( RECIST ) Appearance one new lesion bone scan Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 3 month Any anticancer therapy immunotherapy within 4 week start first dose Confirmed history current autoimmune disease diseases result permanent immunosuppression require permanent immunosuppressive therapy Prior radiotherapy ( local palliative radiotherapy permit ) History allergic reaction monoclonal antibody therapy History clinical significant cardiac disease : include unstable angina , acute myocardial infarction within 6 month prior first study treatment , congestive heart failure â‰¥New York Heart Association ( NYHA ) Class III ) , arrhythmia require therapy except betablockers , calcium channel blocker digoxin uncontrolled hypertension , despite optimal medical management Clinically relevant finding electrocardiogram ( ECG ) second thirddegree AV block , prolongation QRS complex 120 msec QT interval correct heart rate ( QTc ) interval 450 msec Current evidence history uncured ( i.a . absolute risk latent infection ) hepatitis B C human immunodeficiency virus ( HIV ) infection Chronic systemic corticosteroid therapy immunosuppressive therapy stop screen start Seizure disorder require therapy ( steroids antiepileptic ) Subjects unable inject study drug subcutaneously intend s.c. application Nonsuitable central venous access intend c.i.v . administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Bispecific T-cell Engager ( BiTE )</keyword>
</DOC>